在Oct-4和E1A之间的联系:对胚胎干细胞基因调控的影响
H R Schöler1, T Ciesiolka, P Gruss
1Department of Molecular Cell Biology, Max Planck Institute of Biophysical Chemistry, Göttingen, Federal Republic of Germany.
Cell
|July 26, 1991
概括
Oct-4和E1A蛋白质可以独立于距离激活基因转录. 它们的特异比对效率至关重要,这表明E1A在多能细胞中充当了Oct-4的桥梁因素.
科学领域:
- 分子生物学分子生物学
- 发展生物学 发展生物学
- 基因法规 基因法规
背景情况:
- Oct-4是早期小鼠胚胎多能原始细胞中的关键转录因子.
- 异位细胞与异位细胞的远位基因激活需要额外的因素.
研究的目的:
- 调查Oct-4和E1A在激活基底转录机制方面的充分性.
- 确定Oct-4与E1A比率在转录激活中的作用.
- 为了阐明Oct-4介导的转录激活的机制.
主要方法:
- 在细胞系统中,Oct-4和E1A的共同表达.
- 独立于距离的基因激活的分析.
- 生物化学测试用于研究蛋白质-蛋白质相互作用和域要求.
主要成果:
- Oct-4和E1A足以使基底转录的激活独立于距离.
- Oct-4与E1A的比率至关重要;任何一个因素的较高水平都会降低效率.
- 激活需要在Oct-4上有一个事务激活域和E1A的保存域3,它绑定Oct-4.
- E1A 作为 Oct-4 和基底转录启动复合体之间的桥梁因素.
结论:
- E1A促进了Oct-4与基底转录机械的相互作用.
- 提出了一个模型,其中E1A类因子在多能细胞中的Oct-4桥梁.
- 这一发现揭示了多能性和基因表达的调节机制.
相关概念视频
Embryonic Stem Cells
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
Combinatorial Gene Control
Combinatorial gene control is the synergistic action of several transcriptional factors to regulate the expression of a single gene. The absence of one or more of these factors may lead to a significant difference in the level of gene expression or repression.
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
Embryonic Stem Cells
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
Maintenance of the ES Cell State
The cells of the blastocyst inner cell mass only remain pluripotent for a short time. This state of pluripotency and self-renewal can be maintained in embryonic stem (ES) cell culture by adding specific chemicals or growth factors to ensure the cells can continue dividing and later differentiate into different cell types. In some cases, the cells are grown on a feeder layer of differentiated cells, which provides the growth factors and extracellular matrix components necessary for stem cell...
Somatic to iPS Cell Reprogramming
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...
Methods of Nuclear Reprogramming
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for injury repair.


